Q2 2023 Biosyent Inc Earnings Call Transcript
© -
Hello and welcome to the BioSyent Inc. Q2 and First Half 2023 Results Presentation. My name is René Goehrum and I'm the President and CEO of the company. I want to bring your attention to our disclaimer regarding forward-looking statements and we'll dive into the presentation looking first at our sales results in the quarter.
So this is for the period ending June 30, 2023, on a quarter basis and on a half basis. You can see our Canadian Pharmaceutical business performed well at 23% growth, reaching just over $7.7 million and on a 6-month basis for the first half, up 12%. The drivers of this performance could be characterized across the portfolio and we had a strong performance on FeraMAX at 25% up for the quarter, Tibella at 49%, Combogesic and RepaGyn showing a slightly less growth. And then looking at those brands on a 6-month basis, you can see FeraMAX up 13%, Tibella up 44%. Some decline in the Combogesic business that was notable from the first quarter. Obviously, we made up for some of that ground in the second
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
